NeOnc Technologies Holdings, Inc.

About NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. is a biotechnology company focused on developing innovative drug delivery platforms to treat central nervous system (CNS) diseases, particularly brain cancers. Their proprietary technology bypasses the blood-brain barrier (BBB) to deliver therapeutics directly to the brain, aiming to improve treatment efficacy for patients with conditions like Glioblastoma.

Products & Services

NEO100:An intranasal therapy targeting aggressive brain cancers, designed to bypass the blood-brain barrier. It has received FDA Orphan Drug and Fast Track designations and shows promise in improving therapeutic efficacy for brain-based cancers.

NEO212:A brain cancer therapy under clinical trials, showing potential to enhance radiosensitivity and cytotoxicity in glioblastoma tumors, inhibit migration and invasion of glioma stem cells, and treat other conditions like acute myeloid leukemia.

NEO214:A therapeutic shown to be a mediator of cell death in patients with TMZ-resistant glioblastoma and effective against multiple myeloma cells with stronger impact than its individual components.

NEO400:A therapeutic with potential effects on UV-induced skin damage as demonstrated in research studies.

NEO100

NEO212

NEO400

Specialties

Drug Delivery Platforms Central Nervous System (CNS) Therapeutics Brain Cancer Treatment Blood-Brain Barrier Bypass Technology Intranasal Delivery Intra-Arterial Delivery Conjugated Delivery CNS therapeutics Blood-brain barrier drug delivery Brain cancer treatment Intranasal and transfemoral therapeutic delivery

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Insider Equity Purchase T: - FT: Insider Equity Purchase	A: 500000 MR: - FA: over $500,000 FAN: 500000	D: 2026-05-05 FD: 2026-05-05	1 investors
2	RT: PIPE T: - FT: PIPE	A: 16000000 MR: - FA: up to approximately $16 million FAN: 16000000	D: 2026-01-30 FD: 2026-01-30	1 investors
3	RT: Strategic Partnership T: - FT: Strategic Partnership	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2025-10-06 FD: 2025-10-06	1 investors
4	RT: Strategic Investment T: - FT: Strategic Investment	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2025-08-11 FD: 2025-08-11	1 investors
5	RT: Grant T: - FT: Grant	A: 2500000 MR: - FA: $2.5 million FAN: 2500000	D: 2025-08-07 FD: 2025-08-07	1 investors
6	RT: Equity Investment T: - FT: Equity Investment	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2025-07-29 FD: 2025-07-29	1 investors
7	RT: Equity Investment T: - FT: Equity Investment	A: 50000000 MR: - FA: $50 million FAN: 50000000	D: 2025-07-08 FD: 2025-07-08	1 investors

Insider Equity Purchase Latest

2026-05-05

$500K

1 investor (Pro only)

PIPE 2026-01-30

$16.0M

Strategic Partnership 2025-10-06

$50.0M

View 6 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Alan Chiang

Board Director and Scientific Advisory Board Member

A

Amir F. Heshmatpour

CEO, Executive Chairman, and President

B

Bader Al Monawer

Board Director

J

Jim Delshad

Board Director

S

Steven L. Giannotta

Board Director and Scientific Advisory Board Member

T

Thomas Chen

Founder, CSO, Board Director

View 18 more team members with Pro

Unlock Full Team Directory

Recent News